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ABSTRACT
◥
Treatment-eradicated cancer subclones have been reported in
leukemia and have recently been detected in solid tumors. Here we
introduce Differential Subclone Eradication and Resistance (DSER)
analysis, a method developed to identify molecular targets for
improved therapy by direct comparison of genomic features of
eradicated and resistant subclones in pre- and posttreatment sam-
ples from a patient with BRCA2-deficient metastatic prostate
cancer. FANCI and EYA4 were identified as candidate DNA
repair–related targets for converting subclones from resistant to
eradicable, and RNAi-mediated depletion of FANCI confirmed it as
a potential target. The EYA4 alteration was associated with adjacent
L1 transposon insertion during cancer evolution upon treatment,
raising questions surrounding the role of therapy in L1 activation.
Both carboplatin and enzalutamide turned on L1 transposon
machinery in LNCaP and VCaP but not in PC3 and 22Rv1 prostate
cancer cell lines. L1 activation in LNCaP andVCaPwas inhibited by
the antiretroviral drug azidothymidine. L1 activation was also
detected postcastration in LuCaP 77 and LuCaP 105 xenograft
models and postchemotherapy in previously published time-
series transcriptomic data from SCC25 head and neck cancer cells.
In conclusion, DSER provides an informative intermediate step
toward effective precision cancer medicine and should be tested in
future studies, especially those including dramatic but temporary
metastatic tumor regression. L1 transposon activation may be a
modifiable source of cancer genomic heterogeneity, suggesting the
potential of leveraging newly discovered triggers and blockers of L1
activity to overcome therapy resistance.
Significance: Differential analysis of eradicated and resistant
subclones following cancer treatment identifies that L1 activity
associated with resistance is induced by current therapies and
blocked by the antiretroviral drug azidothymidine.
Introduction
Understanding the emergence of cancer-cell resistance to therapy
is central to improving cancer outcomes. A resistant cancer-cell
subclone is relatively easy to define—it is a population of cancer
cells remaining after a patient has received therapy targeting
the original cancer-cell population. By contrast, a cancer-cell sub-
clone eradicated by therapy is relatively hard to define, because it
requires reasonable proof that the eradicated subclone no longer
exists in the patient after a specific therapy. It is also critical to
recognize that key characteristics of an eradicated subclone cannot
be imputed solely from characteristics in a resistant subclone,
because the point at which characteristics defining resistance arose
is not known a priori.
The first cancer subclones genomically proven to be eradicated by
specific therapy were reported in 2015 in leukemia (1), where the focus
was largely on the emergence of resistance rather than on character-
istics of the eradicated subclone. We recently reported a clinically
important subclone eradicated by carboplatin chemotherapy in a
metastatic prostate cancer (mPC) patient “A34” (2). To our knowl-
edge, this is thefirst reported genomic evidence of subclone eradication
in a solid tumor, a metastatic prostate cancer where we previously
reported somatic L1 retrotransposon activity as a source of traceable
genomic heterogeneity (3).
Taken together, these findings led us to hypothesize that (i) Pro-
spectively planned, side-by-side Differential Subclone Eradication and
Resistance (DSER) genomic analysis in individual patients with partial
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responses could provide a uniquely powerful intermediate step for
advancing precision cancer medicine, and (ii) L1 activation itself is a
dynamic source of genomic heterogeneity leading to eradicability or
resistance, and perhaps this response could be blocked by existing
medications.
Materials and Methods
A34 samples and DNA data
Tissue and blood samples from patient A34 were collected as part
of the Project to Eliminate lethal Cancer (PELICAN) integrated
clinical-molecular autopsy study of lethal prostate cancer (Table 1).
The patient gave informed written consent to participate in the John
Hopkins Medicine Institutional Review Board (IRB)–approved
study. Detailed specimen isolation and analysis methods are con-
tained in Woodcock and colleagues (2) and in Supplementary
Methods.
Identification of L1 insertion sites
Whole-genome sequencing (WGS) reads aligned to hg19
from A34 metastatic samples were analyzed for somatic L1 inser-
tions (solo-L1 insertions or L1-mediated transductions) using
TraFiC-mem v1.1 (Supplementary Methods, Supplementary
Table S1; ref. 3).
Generation and analysis of CpG methylation data
From A34 metastatic and autopsy blood DNA samples, paired-
end reads generated from Illumina TruSeq Methyl Capture
EPIC libraries were quality controlled, trimmed, and aligned to
hg19 genome using Bismark v0.22.3 and Bowtie v2.3.4.1.
MethylKit v1.11.0 was used for differential methylation analysis
(Supplementary Methods).
Cell culture
LNCaP and 22Rv1 cells were cultured in a humidified CO2-incu-
bator at 37C in Gibco RPMI 1640 (1X) media (Thermo Fisher
Scientific) supplemented with 10% FBS (Gibco standard FBS, Thermo
Fisher Scientific), 2 mmol/L L-glutamine (Gibco, Thermo Fisher
Scientific), and combination of 100 U/mL Penicillin and 100 mg/mL
Streptomycin (Gibco Pen Strep, Thermo Fisher Scientific). For VCaP
cells, DMEM (Gibco, Thermo Fisher Scientific) supplemented with
10% FBS (GE Healthcare HyClone) and for PC3 F-12 K medium
supplemented with 10% FBS, and antibiotics as for LNCaP growth
mediumwas used. Cell lines were obtained fromATCC, authenticated
using STR (short tandem repeat) markers and Mycoplasma tested
(Supplementary Methods).
Exposure of cell lines to carboplatin/enzalutamide alone
Carboplatin or enzalutamide (ENZ) dissolved in DMSO and
culture medium without FBS was added after a 24-hour initial
incubation period. To control cells DMSO diluted in culture
medium was added to a final concentration of 0.02%. LNCaP
prostate cancer cells were transfected with L1 plasmid or positive
and negative control plasmids and treated with carboplatin (5
mmol/L) or ENZ (10 mmol/L) the day after transfection, and cells
were monitored for 5 days.
Exposure of cell lines to carboplatin/ENZ and
azidothymidine
First, the potential cell toxicity of azidothymidine (AZT) alone was
determined and no effects of AZT on cell viability were seen up to
50 mmol/L tested in LNCaP or VCaP cells (Supplementary Fig. S1).
Next, AZTwas introduced to both LNCaP andVCaP cells alone and in
combination with carboplatin or ENZ.
L1-EGFP retrotransposition assay
The setup of the retrotransposition assay and the creation of the
plasmids containing an L1RP (4) element tagged with GFP were as
described byOstertag and colleagues (5) and implemented as shown in
Faulkner and colleagues (6) with modifications (Supplementary
Methods).
siRNA silencing
LNCaP or PC3 cells were reverse transfected with 25 nmol/L
siRNAs against FANCI (Dharmacon, ON-TARGETplus SMART-
pool, L-022320–01–0005) or Scr control (Dharmacon, nontargeting
pool), using OPTI-MEM and Lipofectamine 2000 transfection
reagent (Invitrogen) in 3 biological replicates on 12-well plates.
Table 1. A34 samples and data studied.
Available sequencing data









SacralBoneMet 11 years prior to death e 0.86 Yes Yes Yes 5,181
Serum 11 years prior to death — 0.04 No Yes No —
Prostate 9 years prior to death X 0.70 No Yes No —
Prostate 9 years prior to death Y 0.67 No Yes No —
Prostate 9 years prior to death Z 0.84 No Yes No —
LiverMet1 Autopsy c 0.84 Yes Yes Yes 12,745
LiverMet12 Autopsy d 0.85 Yes Yes Yes 13,762
LiverMet3 Autopsy a 0.79 Yes Yes Yes 12,332
Serum Autopsy — 0.56 No Yes Yes —
Plasma Autopsy — 0.63 No Yes Yes —
Note: For each of the 10 samples used in the study, the identifiers and time of sample collection is indicated, along with sequencing data types available. Purity for
samples with WGS data was inferred using the Battenberg algorithm (https://github.com/cancerit/cgpBattenberg) and purity for samples without WGS data was
based on the variant allele frequency information and the DPClust algorithm as described inWoodcock and colleagues (2). Numbers of substitutions per sample are
based on the WGS data as analyzed in Gundem and colleagues (8). The number of variants per subclone can be found in Supplementary Table S4. WGS reference
normal spleen DNA is not included in the table.
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Samples were collected after 72 hours for mRNA isolation (Sup-
plementary Table S2).
Cell proliferation assay
For cell proliferation assays, cells were reverse transfected with
25 nmol/L siRNAs against FANCI (Dharmacon, ON-TARGETplus
SMARTpool, L-022320–01–0005) or Scr control (Dharmacon, non-
targeting pool), using OPTI-MEM and Lipofectamine 2000 transfec-
tion reagent (Invitrogen) in 4 biological replicates in a 384-well plate.
LNCaP cells were plated on thewells (1000 cells/well) in antibiotic-free
regular growth medium (Supplementary Methods).
qRT-PCR
The isolation of RNA from cell lines was conducted using TriPure
Isolation Reagent (Roche) following the manufacturer’s protocol.
The concentration of the RNA samples was measured using Nano-
Drop One/OneC Microvolume UV-Vis Spectrophotometer, followed
by dilution of the samples to 1mg/mL. The conversion of 1mg of RNA to
cDNA was done using Transcriptor First Strand cDNA Synthesis Kit
(Roche) according to the manufacturer’s instructions (Supplementary
Methods, Supplementary Table S3).
Western blot
Whole-cell lysates (WCL) were prepared using SDS sample buffer
(66 mmol/L Tris-HCl pH 6.8, 13% glyserol, 2.1% SDS, and 0,01%
Bromophenol Blue) with protease inhibitor added (cOmplete Protease
Inhibitor Cocktail, Roche; Supplementary Methods).
Estimation of L1 mRNA levels from RNA sequencing
RNA sequencing (RNA-seq) reads were quality controlled (Trim-
Galore v0.6.5), trimmed (Cutadapt v1.18), and aligned to the
hg38 genome (STAR v2.7.8 with Gencode Release 33 annotations).
featureCounts v2.0.2 (7) was used to quantify reads within 146
putatively retrotransposition-active human L1 elements with intact
ORF1 and ORF2 as annotated in the L1Base2 database. Counts were
normalized in each sample to represent the number of reads mapping
to the putatively active L1 elements per million aligned reads in the
sample (Supplementary Methods).
Results
Distinct eradicated and resistant subclones
Patient A34 presented with 19 distinct subclones across his primary
tumor and metastases that could be identified via analysis of DNA
single-nucleotide variants and indels using the DPClust method as
previously shown (Supplementary Table S4; ref. 2). Four cancer
subclones specific to the sacral bone metastasis removed at surgery
11 years prior to death were also present in serum and transurethral
resection of the prostate cancer samples prior to carboplatin chemo-
therapy, but absent from three liver metastases and serum and plasma
sampled at autopsy, consistent with eradication by carboplatin che-
motherapy (Fig. 1A; Supplementary Fig. S2; ref. 2). Neither androgen
deprivation therapy nor radiation therapy were the cause of this
subclone eradication because one of the eradicated subclones is still
detected in samples Z, X, and Y that were obtained by transurethral
resection from the prostate after androgen deprivation and after
radiation therapy to the prostate, sacrum, lung, and penis (Fig. 1A;
Supplementary Fig. S2). Resistant subclones (but not eradicated sub-
clones) were detected in the liver metastases and autopsy blood
samples, with subclone detection in autopsy serum and plasma
consistent with separate shedding of tumorDNA into blood by distinct
liver metastases. Based on these findings, if eradicated subclones
were still present in A340s body at the time of death, there is a
reasonable expectation that they would have shed tumor DNA
detectable by the deep targeted sequencing performed, and no such
signals were detected (Fig. 1A).
Genomic lesions potentially conferring eradicability
We analyzed A34 WGS and deep targeted sequence data previ-
ously reported (2, 8), and supplemented this with genome-wide
CpG methylation data to investigate the potential causes of selective
cancer subclone eradication and resistance. Despite the presence of
4825 total substitutions in the eradicated subclones, with identified
truncal drivers including biallelic inactivation of BRCA2, PTEN
LOH, mutations in CEBPA and ARID1A and subclonal FOXA1
amplification, subclones 15, 14, 13, and 12 were eradicated by
carboplatin and etoposide chemotherapy (Fig. 1A; Supplementary
Fig. S2; refs. 2, 8).
Since BRCA2-deficient tumors have recently been proven respon-
sive to chemotherapy leveraging their decreased DNA-repair capac-
ity (9, 10), we hypothesized that the eradicated subclonesmay have had
additional genomic lesions conferring increased sensitivity to DNA
damage. We searched for alterations in currently known members of
DNA repair pathways. The chemotherapy-eradicated subclone har-
bored a 40Mbp heterozygous deletion in the q-arm of chromosome 15
that contains 295 protein-coding genes, 4 of which have functions
involving DNA repair (NEIL1, FANCI, POLG, and BLM; Supplemen-
tary Figs. S3 and S4A). Of these, FANCI is of particular interest as it
belongs to the same Fanconi anemia gene family as BRCA2, regulates
recruitment of the Fanconi anemia core complex at sites of DNA
damage independent of FANCD2 (11), and has been previously shown
to reduce BRCA1/2–deficient cell survival when depleted in an ovarian
cancer model (12). Additionally, FANCI is the only DNA repair gene
within the region deemed essential for prostate cancer cells in CRISPR
knockout experiments from the PICKLES database (Supplementary
Fig. S4B; ref. 13).
Extending the analysis to somatic L1 transposon transduction
during the evolution of metastases in A34, we used updated L1
detection algorithms to increase the resolution of these findings,
identifying a total of 50 L1 insertion events across A34 cancer DNA
samples (Fig. 1B; Supplementary Tables S1–S5). Notably, we observed
repeated unique transductions from the same source elements on
chrXp22.2, chr22q12.1, chr13q21.2, and chr5q21.3 across the L1
somatic evolutionary tree (Fig. 1B; Supplementary Table S1). All of
these elements have recently been shown to be recurrent sources of L1
transductions in multiple cancer types, including prostate, with the
elements on chrXp22.2 and chr22q12.1 being particularly frequent
sources of transductions (14).
The eradicated sacral bone metastasis subclone harbored a unique
profile of 7 L1 insertions not found in the resistant subclones, one of
which was a 595 bp L1 transduction from the chromosome Xp22.2
source element into the TARID gene intron 3 (Fig. 1B). TARID
functions as a promoter demethylase and forms a sense–antisense
gene pair with the gene EYA4, suggesting that TARIDmay have a role
in EYA4 transcriptional regulation (15, 16). Accordingly, we found the
EYA4 promoter significantly hypermethylated in the eradicated sacral
bone metastasis compared with the resistant liver metastases and
autopsy blood samples [66/122 (54%) CpG sites; Fig. 1C]. Transcrip-
tome analysis of the sacral bonemetastasis was not possible because no
remaining tissue material is available, but the increasedmethylation of
the EYA4 promoter region nonetheless points to possible lower levels
of expression of EYA4. Previous studies have found cells with an
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Figure 1.
Genomic evolutionary analysis of primary and metastatic samples and subclones in patient A34 reveals distinct genomic features in resistant and eradicated
subclones. A, Subclonal structure of the lethal metastatic prostate cancer of patient A34, modified fromWoodcock and colleagues (2), presented as a phylogenetic
tree and subclone and sample button plot. Of the 19 total subclones, 17were used to construct the phylogenetic tree (two subcloneswere excluded as they contained
>50% indels). The red box denotes subclones eradicated by treatment that were not detected in autopsy samples, and the light blue box outlines subclones found at
autopsy that resisted chemotherapy. In the phylogenetic tree, dotted lines connect the final subclone of a lineage with a letter denoting the sample or samples in
which it was observed. The color of each subclone reflects its location as shown in the key. Red numbers indicate the total number of substitutions present at each
point in the phylogenetic tree basedonWGSdata. Thebutton plot also illustrates the subclones detected in each sample,with the areaof each circle corresponding to
the cancer cell fraction (CCF) of the subclone [CCF of 1 is found in the top (truncal) nodes of the plot]. Circles outlinedwith dashes indicate subclones not detected in a
sample. Below the button plot, the treatment exposure of samples from patient A34 is shown as a matrix. Eradicated subclones continued to exist after exposure to
external beam radiation and androgen deprivation, and therefore subclone eradication is associated with carboplatin plus etoposide chemotherapy. Samples are
labeled according to the time of collection (yrsptd, years prior to death) and location. The SacralBoneMet sample is a spinal cord compressing sacral nerve root
metastasis removed 11 yrsptd of the patient. B, Circos plot tree of L1 insertion events in the WGS samples from A34. Curved lines are L1 transductions with a
determined source element, with each line colored according to the chromosome of its source. Black triangles denote solo L1 integration sites (source element
unknown). Somatic L1 integration in TARID specific to the eradicated subclone is marked. C, Barplots of methylation percentage in the CpG island in the promoter
region of theEYA4gene,whichmaybe affectedby the L1 insertion into the 30 adjacent sense–antisensepairedTARIDgene in theSacralBoneMet sample. Solid colored
bars indicate significantly hypermethylated sites in the SacralBoneMet (black) relative to the same genomic positions in the LiverMet samples and autopsy blood
samples (cyan). Violin plots showmethylation percentage at the significantly hypermethylatedCpG sites in the EYA4gene promoter, potentially as a consequence of
L1 insertion into TARID. D, Knockdown of FANCI reduces the proliferation of LNCaP but not PC3 cells. Scrambled (Scr) control siRNA was used as reference. The cell
confluence was determined after a 5-day knockdown using IncuCyte S3 Image analysis tools. Asterisks indicate significant difference between sample conditions
based on t test.  , P < 0.01.
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absence of EYA4 expression to bemore sensitive toDNAdamage upon
exposure to cisplatin (17, 18).
As a test of the hypothesis that decreased FANCI function could
have contributed to selective subclone eradication, we exposed
prostate cancer cell lines PC3 and LNCaP to FANCI siRNA with
and without carboplatin treatment. The inhibition of FANCI
resulted in a significant decrease in the proliferation of LNCaP
cells while no effect was observed in PC3 cells (Fig. 1D; Supple-
mentary Fig. S4C–S4D, Supplementary Table S2), confirming FAN-
CI’s role in maintaining LNCaP capacity to undergo cell division.
Exposure of siFANCI LNCaP cells to 10 mmol/L carboplatin addi-
tionally significantly decreased proliferation (Supplementary
Fig. S4D). Similar to BRCA2 somatic inactivation in A34, LNCaP
(but not PC3) contains deficient RAD50 and CHEK2 functions
upstream of the BRCA complex, again supporting increased depen-
dency on FANCI in BRCA-deficient tumors (19).
Genomic lesions potentially conferring gradual increase in
resistance to chemotherapy in resistant subclones
The resistant subclones identified in liver metastases, serum, and
plasma contained 8915 total substitutions (Fig. 1A). Additional
potential drivers in these subclones include RB1 S485F mutation,
17p LOH, PDE4B biallelic loss, and amplification of NCOA2
and FOXA1. RB1 S485F is not currently contained in COSMIC (20),
but is predicted to be deleterious by MutationTaster2 (21),
Provean (22), and the International Cancer Genome Consortium
Data Portal.
We also analyzed L1 insertion events as possible contributors to
resistance to chemotherapy, since previous studies have implicated L1
insertion events as the mediators of mutations, deletions, or rearran-
gements in the genome (14), but found none to be shared by all
resistant subclones.
From the clinical timeline (Supplementary Fig. S2), the first round
of carboplatin/etoposide was associated with the longest (approx.
4-year) response window and appears likely to have been the round
when the subclones 15, 14, 13, and 12 were eradicated. Subsequent
rounds of carboplatin/etoposide provided a decrementing response,
consistent with Darwinian selection of subclones resistant to carbo-
platin/etoposide.
Taken together, the comparative genomic analyses of eradicated
and resistant subclones in A340s metastatic cancer support the
concept of high sensitivity to DNA-damaging chemotherapy due
to truncal BRCA2 biallelic inactivation in all subclones, with
enhanced sensitivity to chemotherapy in the eradicated subclones
due to relatively deficient FANCI and EYA4 function and incre-
mentally increasing resistance to carboplatin/etoposide conferred to
resistant subclones harboring RB1 S485 mutation and other
detected alterations. A visual summary of the proposed DSER
analysis for A34 is shown in Fig. 2A–C.
Carboplatin and ENZ induce L1 in prostate cancer cells
Since the pedigree of somatic L1 transposon integration in A34
metastatic cancer cells is substantially different in eradicated and
resistant subclones andmay be associated with differences in response
to chemotherapy, we hypothesized that L1 activity is triggered by
androgen deprivation or chemotherapy itself. To test this hypothesis,
we exposed prostate cancer cell lines to carboplatin or ENZ and studied
L1 retrotransposon activation using a retrotransposition L1-EGFP
reporter assay (Fig. 3A, Supplementary Fig. S5A and S5B). L1 retro-
transposition indicated by green fluorescence appeared in LNCaP
prostate cancer cells 5 days after commencement of exposure to
carboplatin (Fig. 3A). With the same assay, exposure of LNCaP
to ENZ showed a relative increase in L1-EGFP reporter, below
statistical significance relative to control cells (Fig. 3A). We then
examined L1 ORF1 and ORF2 mRNA levels in untreated, 5-day
carboplatin-treated, and 5-day ENZ-treated LNCaP, VCaP, PC3,
and 22Rv1 cells measured by qPCR. Carboplatin induced an
approximately 4-fold increase in ORF1 and ORF2 expression in
LNCaP cells (P ¼ 0.004 for ORF1 and P ¼ 0.139 for ORF2, t test)
and a 7-fold increase in expression in VCaP cells (P ¼ 0.073 for
ORF1 and P ¼ 0.009 for ORF2, t test), but not in PC3 and 22Rv1
prostate cancer cells (Fig. 3B). Notably, ENZ induced ORF1 and
ORF2 expression by 5.5-fold only in VCaP cells (P ¼ 0.022 for
ORF1 and P ¼ 0.026 ORF2, t test; Fig. 3B). These findings taken
together with the L1 insertion events observed in A34 suggest
that induction of L1 transposon activity by chemotherapy and/or
androgen-deprivation therapy may be a contributor to genomic
heterogeneity in cancer cell populations harbored in individual
patients’ tumors.
To test if L1 induction is also occurring in tumor tissues as a
result of antiandrogen treatment, we examined L1 ORF1 and ORF2
mRNA levels using qPCR in patient-derived LuCaP xenograft
models, expanded in intact and castrate mice (LuCaP 77 and
105; ref. 23). Castration resulted in an approximately 3-fold increase
in ORF1 and ORF2 expression in both xenografts (P < 0.001
for ORF1 and P ¼ 0.002 for ORF2 in LuCaP 77, P ¼ 0.005
for ORF1 and P ¼ 0.037 for ORF2 in LUCaP 105; Fig. 3C),
consistent with the cell line data. In a complementary approach,
we additionally quantified L1 expression (see Methods) from pre-
viously published RNA-seq data from the same xenograft mod-
els (24) where castrated mice had higher levels of L1 mRNA
(Supplementary Fig. S6A). We also analyzed previously published
data from a head and neck cancer cell line SCC25 treated with PBS
or with cetuximab for 11 weeks (25) and examined transcriptomi-
cally once per week. Cetuximab-treated cells showed higher L1
mRNA levels during the first 5 weeks of treatment (P ¼ 0.023,
paired t test; Supplementary Fig. S6B). Taken together, these results
suggest that L1 activation under stress may be a common phenom-
enon in cancer.
Antiretroviral drug AZT reverses treatment-induced L1 activity
in prostate cancer cells
As an antiretroviral compound, nucleoside analogue reverse tran-
scriptase inhibitor (nRTI) AZT has previously been reported to
suppress L1 retrotransposition in HeLa cells (26). We hypothesized
that AZT may be able to reduce carboplatin- and ENZ-induced L1
activity. Thus, we explored the effect of AZT on both ORF1 and ORF2
expression alone and in combination with carboplatin or ENZ in
LNCaP and VCaP prostate cancer cells in vitro. In addition, as ENZ-
induced ORF1 and ORF2 expression was only seen in VCaP cells after
a 5-day delay, we included a longer 25-day exposure period for ENZ
and AZT alone and in combination in LNCaP cells to determine
whether ORF1 and ORF2 expression is altered in response to acquired
resistance to ENZ. Next, AZT was introduced to both LNCaP and
VCaP cells alone and in combination with carboplatin or ENZ. The
results revealed that while carboplatin alone induced ORF1 and ORF2
mRNA expression approximately 4-fold compared with control-
treated LNCaP (P ¼ 0.036 for ORF1 and P ¼ 0.013 for ORF2, t test)
and 9-fold compared with control-treated VCaP cells (P ¼ 0.004 for
ORF1 and P ¼ 0.002 for ORF2, t test), AZT alone did not have any
significant effect on basal ORF1 and ORF2 mRNA expression
(Fig. 3D). Moreover, combined administration of carboplatin
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and AZT kept the ORF1 and ORF2 levels at the basal level and no
induction of ORF1 or ORF2 expression was detected in the combi-
nation treated LNCaP (P ¼ 0.045 for ORF1 and P ¼ 0.017 for ORF2,
t test) or VCaP cells (P ¼ 0.004 for ORF1 and P ¼ 0.001 for ORF2,
t test; Fig. 3D). Interestingly, while no significant changes of ENZ
on ORF1 and ORF2 mRNA expression were seen after a 5-day delay
in LNCaP cells, a longer 25-day ENZ incubation significantly induced
ORF1 and ORF2 mRNA expression by 8-fold in LNCaP cells (P ¼
0.014 for ORF1 and P ¼ 0.007 for ORF2, t test). Further, addition
of AZT reduced the ENZ-induced ORF1 andORF2mRNA expression
by 60%, leading to only 3-fold ORF1 and ORF2 induction in
ENZ and AZT combination-treated LNCaP cells (P ¼ 0.038
for ORF1 and P ¼ 0.029 for ORF2, t test; Fig. 3D). AZT was also
able to block L1 transposon activity in the L1-EGFP reporter
assay (P < 0.05, t test) (Supplementary Fig. S6C). Additionally,
AZT blocked the ENZ induced ORF1 and ORF2 mRNA expression
in VCaP cells (Fig. 3D). On the protein level, carboplatin treatment
of LNCaP cells significantly increased the level of L1 ORF1p
produced by the cells, while further addition of AZT returned
ORF1p levels to normal (Supplementary Fig. S6D). These results
suggest that AZT prevents carboplatin- and ENZ-induced ORF1
and ORF2 expression and could be a modulator of cancer genome
heterogeneity induction by L1 activity in cancer cells in patients
during therapy.
Discussion
By combining deep longitudinal analysis of clinical, liquid biopsy,
and tumor genomic data in patient A340s mPC, we identified what we
believe to be the first genomically documented case of differential
cancer subclone eradication and resistance in a solid tumor (2). In the
current study, we sought to delve deeper, to identify potential under-
lying causes of differential susceptibility to therapy, and to test the idea
that DSER analysis could provide a highly informative intermediate
step toward effective precision cancer medicine. DSER can be defined
as a direct comparison of molecular attributes of pre- and posttreat-
ment cancer subclones eradicated by and resistant to therapy to
identify molecular targets for therapeutic conversion of resistant
subclones to an eradicable state.
Our results revealed that in the eradicated cancer subclones of
patient A34, the already-reduced DNA damage repair capacity pro-
vided by BRCA2 biallelic loss may have been potentiated by reduced
activity of EYA4 and/or FANCI. The resistant subclones may have
survived chemotherapy because of a RB1 S485F mutation. As a
Figure 2.
DSER analysis in Case A34. A, Carbo-
platin and etoposide induce DNA dou-
ble-strand breaks, causing histone
H2AX to be targeted by ATM at its
S139 phosphorylation site to form
gH2AX. B, EYA proteins mediate
the dephosphorylation of gH2AX
at the Y142 residue to promote the
repair response to DNA damage. A
lack of EYA protein in the eradicated
subclones and consequent lack of
dephosphorylation enhances cell
death relative to the resistant sub-
clones. If EYA-mediated dephosphor-
ylation occurs, the DNA repair
response proceeds. C, Ubiquitination
of the complex formed by FANCD2
and FANCI is required for activation
of the BRCA DNA repair complex.
If the ubiquitination is inhibited,
this promotes cell death. Since the
presence of FANCI is needed for
FANCD2 ubiquitination, and compen-
satory increase in FANCD2 activity is
known to occur in BRCA2-deficient
tumors (12), absence (and/or reduced
levels) of FANCI would likely lead to
enhanced cell death in the face of DNA
damaging chemotherapy. The RB/E2F
pathway is implicated as a negative
regulator of FANCD2 transcription.
Deleterious RB1 S485F (present in all
three resistant liver metastases) could
lead to increased FANCD2 levels and
enhanced DNA-repair response, lead-
ing to subclone survival during DNA-
damaging chemotherapy.
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Figure 3.
Carboplatin and enzalutamide induce L1 transposon activity in prostate cancer cells, and this activity can be blocked by AZT.A, The effects of carboplatin (5 mmol/L)
or ENZ (10mmol/L) on L1 activity in LNCaP prostate cancer cells analyzed using a retrotransposition L1-EGFP reporter assay and IncuCyte S3 imaging equippedwith a
green fluorescence channel. Representative IncuCyte cell images are shown for untreated, ENZ-, and carboplatin-exposed LNCaP cells with green channel only (L1-
EGFP) and phase contrast. The control plasmids used included two negative controls (L1Neg-EGFP and L1Mut-EGFP) and a positive-control plasmid (L1Pos-EGFP).
The barplot shows L1-positive EGFPþ counts permm2/confluency quantified using IncuCyte. See also Supplementary Fig. S5. B, The effects of carboplatin or ENZ on
ORF1 and ORF2 mRNA expression in LNCaP, VCaP, PC3, and 22Rv1 prostate cancer cells. C, L1 ORF1 and ORF2 mRNA levels from pre- and postcastration xenograft
samples from LuCaP 77 and LuCaP 105 (23). D, The effects of carboplatin and AZT (50 mmol/L) or ENZ and AZT alone and in combination for 5 and 25 days on ORF1
and ORF2 expression in LNCaP cells and for 5 days in VCaP cells. Asterisks indicate significant difference between treatment conditions based on t test.  , P < 0.05;
 , P < 0.01;  , P < 0.001.
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precision-medicine hypothesis-generating system, we believe this type
of analysis could form a new and much needed bridge to more rapid
progress in precision medicine, both in individual patients and in
advancing mechanistic understanding in general. In patient A34 or
cells in vitromimicking A34, could the addition of drugs blocking the
FANCD2 or FANCI, and/or drugs blocking EYA4 activity force the
resistant subclones to be eradicated by platinum/etoposide or DNA-
repair–inhibiting drugs such as olaparib? Because the root observa-
tions are in vivo and naturally developed in human, the differences
observed using DSER are arguably more likely to identify useful
vulnerabilities than studies starting with cell line or animal studies.
Moreover, when hypotheses generated by DSER are tested in vitro and
in animal studies, the power to unravel importantmechanisms is likely
to be substantially amplified.
How can we test the hypothesis that broadly applied DSER
could accelerate progress in precision cancer medicine? The most
dramatic recent advances in metastatic cancer treatment have
occurred in cancers harboring DNA-repair defects (10) and in those
responsive to recently developed immunotherapy methods, but these
treatments typically do not cure the patient. This makes them the best
place to apply DSER. The tools required to do DSER on a broad scale
are relatively modest. First, whole genome-sequenced samples of
tumor and blood are required prior to treatment and at the time of
relapse. What can be learned about any eradicated and resistant
subclones identified in the samples will be directly proportional to
the quality and sufficiency of the samples for integrated clinical and
molecular analysis. Whether or not subclone eradication is common
enough with current partially effective therapies to warrant broader
expansion of a DSER approach should become evident with as few as
perhaps 20 patients with each tumor-treatment–type combination.
This method could be added to existing clinical trials and could be a
specific additional focus of existing large studies of metastatic cancer
such as those reported by Robinson and colleagues (27) and Swanton
and colleagues (28).
Performing DSER in patient A34 caused us to ask whether
L1 transposon activation itself is a targetable source of cancer
genomic heterogeneity leading to differential sensitivity to therapy.
Our results are to our knowledge the first to show that either
carboplatin or enzalutamide can turn on L1 transposon machinery
in cancer cells, and that this induced activation can be blocked
in vitro by the antiretroviral drug AZT. We were surprised to
discover that L1 activation after carboplatin occurs only after a
5-day delay in 2 of the 4 prostate cancer cell lines tested. The delay
may explain why L1 activation was not detected in a previous study
where osteosarcoma cells were studied immediately after cisplatin
exposure (29). These findings indicate that induced L1 activity in
response to stresses such as carboplatin chemotherapy or androgen
deprivation may contribute to genomic heterogeneity-driven resis-
tance to therapy in some cancers.
What remains unknown about somatic L1 induction in cancer is
what initiates the initial binding of RNA Polymerase II to begin the
transposition process. Our results provide a foundation for mecha-
nistic studies of L1 induction, and could help reveal why the prevalence
of somatic L1 induction varies among cancer-cell types (14). In
prostate cancer, we speculate that differences in driver genes and
remaining androgen receptor (AR) response pathways could underlie
the L1 inducibility shown in LNCaP/VCaP cells that is lacking in PC3/
22Rv1 cell lines.
It appears possible that in A34 L1 activity induced by carboplatin
and etoposide chemotherapy could have contributed to genomic
instability leading both to the eradicable and resistant subclones.
Testing whether or not chemotherapy-induced L1 activity is clinically
important or not could be tested in vivo by comparing ctDNA response
with chemotherapy in patients treated with prechemo suppression of
L1 byAZT versus placebo. AZT is currently included in several clinical
trials in leukemia, lymphoma, and other cancers. The impact of AZT
on L1 activation could be studied in samples from patients enrolled in
those trials (30).
In summary, future work testing of DSER-based identification
of novel cancer therapeutic targets, and deeper mechanistic studies
of the role and manipulability of L1 induction in cancer evolution
and therapy could accelerate progress in development of effective
precision oncology.
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